Skip to Content

Franklin Genomic Advancements ETF HELX

Medalist Rating as of | See Franklin Templeton Investment Hub

Morningstar’s Analysis HELX

Will HELX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

The combination of a middling Process Pillar rating and a Below Average People Pillar rating limit Franklin Genomic Advancements ETF to a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings HELX

  • Current Portfolio Date
  • Equity Holdings 56
  • Bond Holdings 0
  • Other Holdings 4
  • % Assets in Top 10 Holdings 42.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Us Dollar

6.64
740,222
Cash and Equivalents
6.28
699,811
Healthcare
6.22
694,064
Healthcare
5.55
619,239
Healthcare
4.61
514,120
Healthcare
4.53
504,996
Healthcare
3.42
381,364
Healthcare
3.28
365,830
Healthcare
2.78
310,349
Healthcare